e-learning
resources
ERJ
2012
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
High initial multidrug-resistant tuberculosis rate in Buenaventura, Colombia: a public–private initiative
Sonia L. Villegas, Beatriz E. Ferro, Carlos M. Perez-Velez, Cesar A. Moreira, Liliana Forero, Ernesto Martínez, Nalin Rastogi, Jose Antonio Caminero
Source:
Eur Respir J 2012; 40: 1569-1572
Journal Issue:
December
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Sonia L. Villegas, Beatriz E. Ferro, Carlos M. Perez-Velez, Cesar A. Moreira, Liliana Forero, Ernesto Martínez, Nalin Rastogi, Jose Antonio Caminero. High initial multidrug-resistant tuberculosis rate in Buenaventura, Colombia: a public–private initiative. Eur Respir J 2012; 40: 1569-1572
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
National advisory services for multidrug-resistant tuberculosis (MDRTB) in Europe: an ERS-TBnet survey
Source: International Congress 2019 – Tuberculosis: treatment and management
Year: 2019
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia)
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Multidrug-resistant and extensively drug resistance tuberculosis has a strong public health and economical impact in the Republic of Moldova
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations
Year: 2013
Rifampicin-resistant tuberculosis (RR-TB) in eastern Europe
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016
A study of tuberculosis in an expatriate Nepalese community in South-East London
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations
Year: 2013
Trend in TB control in Republic of Moldova: High MDRTB burden country
Source: International Congress 2014 – Tuberculosis: epidemiology and public health
Year: 2014
Tb epidemiological situation in Tomsk Oblast civilian sector under the implementation of the subnational grant of the global fund to fight AIDS, tuberculosis and malaria
Source: Annual Congress 2007 - Tuberculosis control
Year: 2007
Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration
Source: Eur Respir J 2016; 47: 686-688
Year: 2016
Is prevalence of MDR TB and XDR TB decreasing in a tertiary care hospital in India?
Source: International Congress 2017 – MDRTB: detection and management
Year: 2017
Cross-border management of tuberculosis cases through an updated ERS/WHO TB consilium
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015
TB endemia – a major priority for public health system in Romania
Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2008
The global response to rifampicin-resistant tuberculosis: Current situation and recent trends
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016
High prevalence of hepatitis C among patients with drug-resistant tuberculosis and its impact on the treatment outcome in Azerbaijan prisons
Source: International Congress 2015 – Screening strategies in TB
Year: 2015
Pattern of drug resistance in TB patients treated at DR TB unit in tertiary care public sector hospital in Karachi Pakistan
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Changing prevalence of MDR TB and XDR TB in a tertiary care hospital in India
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I
Year: 2013
Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe
Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology
Year: 2016
Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement
Source: Eur Respir J 2012; 40: 1081-1090
Year: 2012
Is multidrug-resistant tuberculosis on the rise in Mozambique? Results of a national drug resistance survey
Source: Eur Respir J 2011; 37: 222-224
Year: 2011
The health economics of treating MDR-TB in the Indian private sector
Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system
Year: 2016
Number of tuberculosis (TB) cases reported by primary care physicians (PCPs) in India: Results of a 1-day point prevalence study in 880 urban cities and towns in India
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept